Understand the source comparison
Energy Peptides 2026 Update: Clinical vs Subjective Outcomes Comparison
MOTS-c Mitochondrial biogenesis signalling 18–22% increase in skeletal muscle ATP Moderate to strong (31% Chalder Fatigue Scale improvement) Phase 2 human trials (2026) Strongest evidence for peripheral energy enhancement. Requires consistent twice-weekly dosi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MOTS-c
- Mitochondrial biogenesis signalling
- 18–22% increase in skeletal muscle ATP
- Moderate to strong (31% Chalder Fatigue Scale improvement)
- Phase 2 human trials (2026)
- Strongest evidence for peripheral energy enhancement. Requires consistent twice-weekly dosing for 8+ weeks
- SS-31 (Elamipretide)
- Cardiolipin stabilisation, reduced electron leak
- 12–16% improvement in oxidative phosphorylation efficiency
- Mild to moderate in healthy subjects, strong in mitochondrial disease populations
- Phase 3 trials ongoing
- Best suited for mitochondrial dysfunction states. Limited benefit in metabolically healthy individuals
- Humanin
- STAT3 pathway activation, mitochondrial biogenesis
- Indirect. Increases mitochondrial number rather than per-organelle output
- Mild in isolation, moderate when stacked with MOTS-c
- Phase 1 safety established, Phase 2 pending
- Adjunct role rather than primary agent. Most effective in combination protocols
- MK 677
- IGF-1 upregulation → PGC-1α activation
- Indirect via mitochondrial density increase over 6–8 weeks
- Variable. Appetite stimulation and water retention confound subjective assessment
- Extensive human data for GH release, emerging data for mitochondrial effects
- Useful for long-term mitochondrial density rather than acute energy. Expect 6+ weeks for noticeable effect
- Cerebrolysin
- Neurotrophic modulation, cerebral glucose metabolism
- CNS-specific. Improves neuronal energy efficiency
- Strong for mental fatigue, minimal effect on physical energy
- Phase 4 (approved in 40+ countries for stroke/dementia)
- Best for cognitive energy deficits (brain fog, mental fatigue). Not peripheral muscle energy